As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the American Society of Hematology must ensure balance, independence, objectivity, and scientific rigor in all of the educational activities it sponsors. All authors are expected to disclose any financial relationships with any proprietary entity producing health care goods or services that have occurred within 12 months from the start of or during the production of the work and that are relevant to the author’s content. If an author has such a financial interest, then s/he must disclose the name of the commercial interest and nature of the relationship (e.g., consultant, grantee, etc.). If the author has no such financial relationship, s/he must declare that s/he has nothing to disclose. The intent of this disclosure is not to prevent an author with a significant financial or other relationship from making a presentation, but rather to provide readers with information on which they can make their own judgments. It remains for the audience to determine whether the author’s interests or relationships may influence the work with regard to exposition or conclusion.
Click here to view Disclosures as a table alphabetized by author (PDF, 63.2 KB).
Chapter 1
Molecular basis of hematology
Martha P. Mims, Timothy A. Graubert, and Josef T. Prchal
Dr. Mims: equity: Amgen, IDEC; research funding: Genentech, Imclone, Roche, Novartis.
Dr. Graubert declares no competing financial interest.
Dr. Prchal declares no competing financial interest.
Chapter 2
Consultative hematology
Marc J. Kahn, Amy E. Geddis, and Keith R. McCrae
Dr. Kahn declares no competing financial interest.
Dr. Geddis: research funding: Amgen; membership on board of directors or advisory committee: Amgen.
Dr. McCrae: consultancy:GlaxoSmithKline; honoraria: GlaxoSmithKline.
Chapter 3
Hematopoietic growth factors
David C. Dale and Gary H. Lyman
Dr. Dale: consultancy: Amgen, Biota, Regeneron, Schering-Plough, Tarix, Telik; research funding: Amgen, Genzyme, Merck, Schering-Plough, Telik, Barth Foundation,
National Institutes of Health, University of Washington; honoraria: Amgen, Biota, Caremark, Cellerant, Regeneron, Schering-Plough,Tarix, Telik, BCDecker, Wolters Kluwer Health (Lippincott Williams & Wilkins), American College of Physicians, US Department of Health and Human Services; patents and royalties: book chapters and editing for Wolters Kluwer Health (Lippincott Williams & Wilkins); speakers’ bureau: Amgen; membership on board of directors or advisory committee: Cellerant (Scientific Advisory Board), Schering Plough (Data Safety Monitoring Board).
Dr. Lyman: research funding: Amgen; speakers’ bureau: Amgen.
Chapter 4
Iron metabolism, iron overload, and the porphyrias
Alice D. Ma and Victor R. Gordeuk
Dr. Ma declares no competing financial interest.
Dr. Gordeuk: consultancy: Merck, Amgen, Ikaria; research funding: Merck, TRF Pharma, Biomarin; speakers’ bureau: Novartis.
Chapter 5
Acquired underproduction anemias
Michal G. Rose and Cindy A. Leissinger
Dr. Rose declares no competing financial interest.
Dr. Leissinger declares no competing financial interest.
Chapter 6
Hemolytic anemias
Charles T. Quinn and Charles H. Packman
Dr. Quinn declares no competing financial interest.
Dr. Packman declares no competing financial interest.
Chapter 7
Thrombosis and thrombophilia
Stephan Moll and Janna M. Journeycake
Dr. Moll: consultancy: Bayer, Roche Diagnostics, International Technidyne Corp., Lundbeck, GTC Biotherapeutics, Talecris, Ortho McNeil-Janssen Pharmaceuticals;
research funding: International Technidyne Corp.; honoraria: Lundbeck, Talecris; grant support: CDC grant # 1U01DD000292-0.
Dr. Journeycake: honoraria: Baxter Healthcare; membership on board of directors or advisory committee: Physicians Advisory Council of
Baxter Healthcare; grant support, NIH K23 Career Development
Award (K23 HL0840970).
Chapter 8
Bleeding disorders
Guy Young and Amy D. Shapiro
Dr. Young: consultancy; Novo Nordisk, Baxter, Bayer; honoraria: Novo Nordisk, Baxter, Bayer; membership on board of directors or advisory committee: Novo Nordisk, Baxter, Bayer.
Dr. Shapiro: consultancy: Baxter BioScience, Inspiration Biopharmaceuticals, Syntonix; speakers’ bureau: Baxter BioScience, Novo Nordisk; membership on board of directors or
advisory committee: Baxter BioScience, Novo Nordisk, Bayer Healthcare, Inspiration Biopharmaceuticals, Catalyst Biosciences, American Thrombosis and Hemostasis Network, National Hemophilia Foundation; clinical research protocols: Baxter BioScience, Novo Nordisk, Bayer Healthcare Pharmaceuticals, Wyeth Pharmaceuticals, Inspiration Biopharmaceuticals; NIH/NHLBI: Clinical Trial Review Board, Data Safety Management Board.
Chapter 9
Donald M. Arnold and A. Koneti Rao
Dr. Arnold: consultancy: Amgen Canada; research funding: Hoffmann-La Roche; honoraria: CME lectures accredited by McMaster University, funded by unrestricted educational grant from GlaxoSmithKline.
Dr. Rao declares no competing financial interest.
Chapter 10
Laboratory hematology
Georgette A. Dent and Charles S. Eby
Dr. Dent declares no competing financial interest.
Dr. Eby: consultancy: Barr Pharmaceuticals; research funding: Osmetech, Beckman Coulter, Stago Diagnostica; hono¬raria: Genome Quebec.
Chapter 11
Transfusion medicine
Don L. Siegel and Karen Quillen
Dr. Siegel declares no competing financial interest.
Dr. Quillen declares no competing financial interest.
Chapter 12
Cellular basis of hematopoiesis and stem cell transplantation
Alan B. Cantor, Hillard M. Lazarus, and Ginna G. Laport
Dr. Cantor declares no competing financial interest.
Dr. Lazarus: honoraria: Genentech/Biogen IDEC; speakers’ bureau: Genentech/Biogen IDEC.
Dr. Laport: honoraria: Genzyme.
Chapter 13
Myeloid disorders
Daniel C. Link and Geoffrey L. Uy
Dr. Link declares no competing financial interest.
Dr. Uy: consultancy: Genzyme; research funding: Genzyme, Novartis Oncology; honoraria: Novartis Oncology; speakers’ bureau: Genzyme
Chapter 14
Myeloproliferative neoplasms
Bruno C. Medeiros and Ross L. Levine
Dr. Medeiros: consultancy: Millennium, Antisoma; research funding: Genentech; speakers’
bureau: Celgene, Novartis.
Dr. Levine: consultancy: Novartis, Cephalon, TargeGen (all on a one-time basis); honoraria: Novartis, Cephalon (paid talks).
Chapter 15
Marrow failure syndromes
Jaroslaw P. Maciejewski and David P. Steensma
Dr. Maciejewski declares no competing financial interest.
Dr. Steensma: research funding: Amgen, Johnson & Johnson, Novartis.
Chapter 16
Acute myeloid leukemia
Gail J. Roboz and Lillian Sung
Dr. Roboz: honoraria: Celgene, Eisai, Genzyme, Novartis, Cephalon.
Dr. Sung declares no competing financial interest.
Chapter 17
Acute lymphoblastic leukemia and lymphoblastic lymphoma
Wendy Stock and Ching-Hon Pui
Dr. Stock: consultancy: Hana Biosciences; research funding: Enzon; honoraria: Enzon;
Dr. Pui: honoraria: EUSA Pharma, Sanofi-Aventis.
Chapter 18
Lymphomas
Kerry J. Savage and Stephanie A. Gregory
Dr. Savage: honoraria: Roche, Eli Lilly.
Dr. Gregory: consultancy: Amgen, Genentech; research funding: Amgen, Boehringer Ingelheim, Celgene, CTI, Genentech, GenMab, GlaxoSmithKline, Gloucester Pharmaceuticals, Millennium, NCIC CTG, Rigel Pharmaceuticals; speakers’ bureau: Genentech, GlaxoSmithKline, Millennium.
Chapter 19
Chronic lymphocytic leukemia
Neil E. Kay and Vicki A. Morrison
Dr. Kay: consultancy: Cephalon; research funding: Celgene, Genentech, Polyphenon E International, Hospira; membership on board of directors or advisory committee:
Genentech, Biogen Idec.
Dr. Morrison: speakers’ bureau: Merck, Pfizer, Genentech, Celgene, Amgen; membership on data safety monitoring board or scientific advisory committee: Merck, Celgene.
Chapter 20
Plasma cell dyscrasias
Irene M. Ghobrial, Jacob P. Laubach, and Paul G. Richardson
Dr. Ghobrial: research funding: Millennium; honoraria: Millennium, Celgene; speakers’ bureau: Millennium, Celgene, Novartis; membership on board of directors or advisory committee: Millenium; advisory board: Celgene, Novartis.
Dr. Laubach: membership on board of directors or advisory committee: Novartis; advisory board: Novartis.
Dr. Richardson: speakers’ bureau: Celgene, Millennium, Johnson & Johnson; membership on board of directors or advisory committee: Celgene, Millennium,
Johnson & Johnson; advisory board: Celgene, Millenium.
In compliance with ACCME policy, the American Society of Hematology also requires all authors to disclose any discussion of off-label drug use.
Dr. Arnold will discuss rituximab for ITP.
Dr. Ghobrial will discuss bortezomib in Waldenström macroglobulinemia and use of lenalidomide in upfront therapy for myeloma.
Dr. Gregory will discuss rituximab maintenance after rituximab chemotherapy in lymphoma, radioimmunotherapy for consolidation therapy after chemotherapy for initial treatment of lymphoma, bortezomib and combinations in Waldenström macroglobulinemia, rituximab in hairy cell leukemia, R-CHOP in localized DLBCL, and thalidomide in mantle cell lymphoma.
Dr. Journeycake will discuss anticoagulant agents in children.
Dr. Kay will discuss pentostatin and lenalidomide for CLL.
Dr. Maciejewski will discuss off-label use of cyclosporine A, prednisone, and danazol.
Dr. Moll will discuss new oral anticoagulants rivaroxaban, apixaban, and dabigatran.
Dr. Quillen will discuss use of recombinant factor VII in refractory bleeding.
Dr. Rao will discuss DDVAP for treatment of platelet disorders.
Dr. Richardson will discuss upfront use of lenalidomide.
Dr. Savage will discuss rituximab maintenance after rituximab chemotherapy in lymphoma, radioimmunotherapy for consolidation therapy after chemotherapy for initial treatment of lymphoma, bortezomib and combinations in Waldenström macroglobulinemia, rituximab in hairy cell leukemia, R-CHOP in localized DLBCL, and thalidomide in mantle cell lymphoma.
Dr. Shapiro will discuss rFVIIa as high-dose therapy and for rare disorders.
Dr. Siegel will discuss use of recombinant factor VIIa for bleeding.
Dr. Young will discuss rFVIIa (Novoseven) for management of bleeding in hemophilia at doses and regimens that are not approved and for other off-label indications and prothrombin complex concentrates (various brand names) for treatment of warfarin overdose, vitamin K defi ciency, and liver disease.
